Gilead Sciences, Inc. $GILD Shares Bought by China Universal Asset Management Co. Ltd.

Key Points

• China Universal Asset Management increased its Gilead Sciences position by 20.2% in the third quarter, purchasing 32,575 additional shares. Its holdings totaled 194,103 shares valued at approximately $29.4 million.
• Gilead reported quarterly results above expectations, with adjusted EPS of $2.55 and revenue of $8.3 billion, up 6.8% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $159.81.
• Shares opened at $165.61, near the company’s 12-month high, while insiders sold 111,000 shares worth about $15.9 million over the past 90 days. Longer-term risks include a planned 38% Medicare-related Biktarvy price reduction beginning in 2028.

China Universal Asset Management Co. Ltd. lifted its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 20.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 194,103 shares of the biopharmaceutical company's stock after buying an additional 32,575 shares during the quarter. Gilead Sciences comprises approximately 1.5% of China Universal Asset Management Co. Ltd.'s investment portfolio, making the stock its 13th biggest holding. China Universal Asset Management Co. Ltd.'s holdings in Gilead Sciences were worth $29,364,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Client 1ST Advisory Group LLC lifted its stake in Gilead Sciences by 4.0% in the third quarter. Client 1ST Advisory Group LLC now owns 1,786 shares of the biopharmaceutical company's stock valued at $266,000 after buying an additional 69 shares during the period. Grove Bank & Trust boosted its holdings in Gilead Sciences by 1.2% during the third quarter. Grove Bank & Trust now owns 6,345 shares of the biopharmaceutical company's stock worth $946,000 after buying an additional 74 shares during the last quarter. Financial Connections Group Inc. grew its position in shares of Gilead Sciences by 30.2% during the 1st quarter. Financial Connections Group Inc. now owns 328 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 76 shares during the period. Wilkerson Advisory Group LLC grew its position in shares of Gilead Sciences by 54.2% during the 1st quarter. Wilkerson Advisory Group LLC now owns 222 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 78 shares during the period. Finally, HBW Advisory Services LLC grew its position in shares of Gilead Sciences by 2.4% during the 1st quarter. HBW Advisory Services LLC now owns 3,391 shares of the biopharmaceutical company's stock worth $473,000 after buying an additional 79 shares during the period. 83.67% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

GILD has been the topic of a number of analyst reports. Bank of America increased their price target on shares of Gilead Sciences from $168.00 to $172.00 and gave the company a "buy" rating in a research report on Tuesday, October 20th. Jefferies Financial Group restated a "buy" rating and set a $185.00 price objective on shares of Gilead Sciences in a report on Friday, October 23rd. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $155.00 target price on shares of Gilead Sciences in a research note on Thursday, October 8th. HSBC upped their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the company a "buy" rating in a research note on Thursday, September 10th. Finally, Barclays cut their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 29th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $159.81.

Insider Activity

In other Gilead Sciences news, CEO Daniel O'Day sold 15,000 shares of Gilead Sciences stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $148.64, for a total value of $2,229,600.00. Following the sale, the chief executive officer owned 577,133 shares of the company's stock, valued at $85,785,049.12. This trade represents a 2.53% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the completion of the sale, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. This trade represents a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 111,000 shares of company stock worth $15,877,860. 0.30% of the stock is currently owned by insiders.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly results exceeded expectations. Gilead reported adjusted EPS of $2.55, ahead of the $2.17-$2.19 analyst consensus, while revenue rose 6.8% year over year to $8.3 billion versus expectations of approximately $7.8 billion. Gilead Sciences Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Gilead raised its full-year sales forecast. The company now expects 2026 product sales of $31.0 billion to $31.3 billion, up from its previous range of $30.1 billion to $30.4 billion. The improved outlook reflects strength in HIV medicines and helped support the bullish reaction. Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
• Positive Sentiment: HIV and oncology products drove growth. Biktarvy continued to power the HIV franchise, while cancer drug Trodelvy also contributed to sales growth, giving investors evidence that Gilead’s commercial portfolio is performing better than anticipated.
• Positive Sentiment: Lyvdelzi gained Canadian reimbursement support. A reimbursement agreement with Canada’s pan-Canadian Pharmaceutical Alliance could improve access to Gilead’s liver-disease treatment, though its near-term financial impact is likely limited. Gilead Successfully Completes Negotiations for LYVDELZI
• Neutral Sentiment: Analyst sentiment remains cautious. Robert W. Baird maintained a Hold rating, suggesting the strong results may already be reflected in the stock’s valuation and that investors want clearer evidence of sustainable growth beyond the HIV franchise. Gilead Gets a Hold from Robert W. Baird
• Negative Sentiment: Future pricing pressure is a major risk. Gilead said Medicare negotiations will reduce Biktarvy’s price by 38% beginning in 2028, creating a significant longer-term threat to revenue and margins for one of its most important products. Gilead Hikes 2026 Sales Outlook
• Negative Sentiment: The company widened its 2026 non-GAAP loss forecast. Despite the quarterly beat, the updated loss outlook highlights ongoing expenses and execution risks, tempering the otherwise strong earnings report. Gilead Widens 2026 Non-GAAP Loss Forecast

Gilead Sciences Trading Up 4.0%

Shares of GILD stock opened at $165.61 on Friday. The firm has a fifty day moving average of $150.33 and a 200-day moving average of $139.55. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $165.70.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts' expectations of $7.81 billion. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The firm's revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.47 EPS. On average, analysts predict that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.